Back to Search
STEPHANIE ROZE, M.D.
M.D.
Pediatrics Physician
NPI: 1891721288Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
104480(NY)
Research & Publications (20)
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
PMID 18479280·Int J Clin Pract·2008
4-observational
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
PMID 18400145·Curr Med Res Opin·2008
4-observational
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
PMID 18387067·Value Health·2008
8-other
Cost-effectiveness of diabetes case management for low-income populations.
PMID 17850527·Health Serv Res·2007
8-other
Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
PMID 17850322·Int J Clin Pract·2007
8-other
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.
PMID 17407646·Curr Med Res Opin·2007
4-observational
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
PMID 17355742·Curr Med Res Opin·2007
2-rct
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
PMID 17237927·Eur J Health Econ·2007
8-other
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
PMID 17199725·Diabetes Obes Metab·2007
4-observational
A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease.
PMID 17166337·Curr Med Res Opin·2006
8-other
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
PMID 17076969·Curr Med Res Opin·2006
8-other
Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.
PMID 16939559·Int J Clin Pract·2006
6-review
[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
PMID 16868875·Dtsch Med Wochenschr·2006
8-other
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
PMID 16834840·Curr Med Res Opin·2006
8-other
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
PMID 16779715·Swiss Med Wkly·2006
4-observational
Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
PMID 16709318·Curr Med Res Opin·2006
8-other
Counting the costs of overweight and obesity: modeling clinical and cost outcomes.
PMID 16574040·Curr Med Res Opin·2006
8-other
Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.
PMID 16523189·Diabetes Metab·2006
8-other
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
PMID 16368057·Curr Med Res Opin·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 47 MARCUS GARVEY BLVD
BROOKLYN, NY 11206 - Phone
- (718) 445-3884
Quick Facts
- NPI
- 1891721288
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile